GARDASIL™ Vaccine Impact in Population Study (V501-033)

CompletedOBSERVATIONAL

Enrollment

54,516

Participants

Timeline

Start Date

May 29, 2007

Primary Completion Date

December 2, 2014

Study Completion Date

December 2, 2014

Conditions

Human Papillomavirus Infections

All Listed Sponsors

collaborator

Danish Cancer Society

OTHER

collaborator

Union for International Cancer Control

OTHER

collaborator

Norwegian Institute of Public Health

OTHER_GOV

collaborator

Karolinska Institutet

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01077856 - GARDASIL™ Vaccine Impact in Population Study (V501-033) | Biotech Hunter | Biotech Hunter